News from sorrento therapeutics, inc. A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Sep 10, 2013, 08:15 ET

Sorrento Therapeutics Secures Rights to Biomiga Diagnostics' Therapeutic Drug Monitoring Device for Development of Personalized Paclitaxel Cancer Therapy

 Sorrento Therapeutics, Inc. (OTC QB: SRNE; Sorrento) announced today that it has secured an option to an exclusive license for the worldwide...

Sep 10, 2013, 08:00 ET

Sorrento Therapeutics Completes IgDraSol Merger

 Sorrento Therapeutics, Inc. (OTC QB: SRNE; Sorrento) announced today that it has completed the merger with IgDraSol, Inc., a privately-held...

Sep 06, 2013, 08:00 ET

Sorrento Therapeutics to Present at Two Healthcare Conferences

Sorrento Therapeutics, Inc. (OTC QB: SRNE; Sorrento) announced today that Dr. Henry Ji, President and CEO, will present a corporate overview at two...

Aug 05, 2013, 08:00 ET

Sorrento Therapeutics and IGDRASOL Proceed with Development of Cynviloq™ under 505(b)(2) Bioequivalence Regulatory Pathway

 Sorrento Therapeutics, Inc. (OTCQB: SRNE; SRNED; Sorrento) and IGDRASOL announced today that IGDRASOL has received official meeting minutes...

Aug 01, 2013, 08:00 ET

Sorrento Therapeutics Announces Reverse Split of Common Stock

Sorrento Therapeutics, Inc. (OTCQB: SRNE; Sorrento) announced today that it has filed a Certificate of Amendment to its Restated Certificate...

Jul 09, 2013, 09:00 ET

Sorrento Therapeutics and Ben-Gurion University Sign an Agreement for the Development of Anti-Hepatitis C Virus Antibodies

Sorrento Therapeutics, Inc. (OTCQB: SRNE; Sorrento) and B.G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD. announced today that they have entered...

Jul 01, 2013, 09:00 ET

Sorrento Therapeutics, Inc. and IGDRASOL Will Present Preliminary Phase III Data Analysis for Cynviloq at the 4th International Nanomedicine Conference in Sydney, Australia

Sorrento Therapeutics, Inc. (OTCQB: SRNE; Sorrento) and IGDRASOL announced today that the companies will present Phase III interim data analysis of...

Jun 24, 2013, 06:00 ET

Sorrento Therapeutics Presents Preclinical Data of its Fully Human Antibody Programs Targeting Anti-PD-L1 and Anti-PD-1 at the 8th Annual Next Generation Protein Therapeutics Summit

 Sorrento Therapeutics, Inc. (OTCQB: SRNE; Sorrento) announced today that preclinical data of its therapeutic fully human anti-PD-L1 and...

Jun 21, 2013, 05:00 ET
Jun 06, 2013, 05:00 ET

Sorrento Therapeutics Receives Frost & Sullivan's 2013 Global Investment Opportunity Award in Oncology

 Sorrento Therapeutics, Inc. (OTCBB: SRNE) today announced that it has been awarded the 2013 Frost & Sullivan Global Investment Opportunity...

May 30, 2013, 20:15 ET

Sorrento Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference in New York City

Sorrento Therapeutics (OTCBB: SRNE; or STI) today announced that Henry Ji, Ph.D., the Company's President and Chief Executive Officer, will present...

May 28, 2013, 05:00 ET
May 17, 2013, 16:29 ET

Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases

 Sorrento Therapeutics, Inc. (OTCBB: SRNE; or STI) announced today that its Fast-Track Advanced Technology Small Business Technology Transfer...

May 13, 2013, 16:00 ET

Sorrento Therapeutics, Inc. and IGDRASOL Announce the Acquisition of Exclusive Distribution Rights to Cynviloq™ for the European Union

 Sorrento Therapeutics, Inc. ("STI"; SRNE) and IGDRASOL announced today the acquisition of exclusive distribution rights from Samyang...

Apr 08, 2013, 00:17 ET

Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain

Sorrento Therapeutics, Inc. ("STI"; SRNE) and IGDRASOL announced today that IGDRASOL will be presenting updates of its analysis of proprietary late...

Mar 31, 2013, 22:05 ET

Sorrento Therapeutics, Inc. and IGDRASOL Announce Three Presentations on Cynviloq™ (IG-001; paclitaxel polymeric micelle) at the American Association of Cancer Research (AACR) Meeting

 Sorrento Therapeutics, Inc. ("STI"; SRNE) and IGDRASOL announced today that IGDRASOL will be presenting updates of its development of...

Mar 07, 2013, 06:17 ET

Sorrento Therapeutics Signs Exclusive Option to Acquire IGDRASOL

 Sorrento Therapeutics, Inc. ("STI"; SRNE: OB) today announced that it has signed an exclusive option to acquire IGDRASOL, a private company...

Jan 08, 2013, 06:00 ET

Sorrento Therapeutics acquires rights to produce recombinant intravenous immunoglobulins (rIVIG)

 Sorrento Therapeutics, Inc. (STI; OTCBB: SRNE) today announced that it has acquired worldwide rights that will allow for the application of...

Jun 07, 2012, 20:40 ET

Sorrento Therapeutics Awarded Third Phase I STTR Grant

Sorrento Therapeutics, Inc. (OTCBB: SRNE) today announced that it has received an Advanced Technology Small Business Technology Transfer Research...

Jul 28, 2011, 20:44 ET

Sorrento Therapeutics Awarded Phase I STTR Grant for C. difficile Program

Sorrento Therapeutics, Inc. (OTC Bulletin Board: SRNE) announced today that it has received a Phase I Small Business Technology Transfer Research...